176 related articles for article (PubMed ID: 28892380)
1. GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).
Romero FA; Murray J; Lai KW; Tsui V; Albrecht BK; An L; Beresini MH; de Leon Boenig G; Bronner SM; Chan EW; Chen KX; Chen Z; Choo EF; Clagg K; Clark K; Crawford TD; Cyr P; de Almeida Nagata D; Gascoigne KE; Grogan JL; Hatzivassiliou G; Huang W; Hunsaker TL; Kaufman S; Koenig SG; Li R; Li Y; Liang X; Liao J; Liu W; Ly J; Maher J; Masui C; Merchant M; Ran Y; Taylor AM; Wai J; Wang F; Wei X; Yu D; Zhu BY; Zhu X; Magnuson S
J Med Chem; 2017 Nov; 60(22):9162-9183. PubMed ID: 28892380
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.
Crawford TD; Romero FA; Lai KW; Tsui V; Taylor AM; de Leon Boenig G; Noland CL; Murray J; Ly J; Choo EF; Hunsaker TL; Chan EW; Merchant M; Kharbanda S; Gascoigne KE; Kaufman S; Beresini MH; Liao J; Liu W; Chen KX; Chen Z; Conery AR; Côté A; Jayaram H; Jiang Y; Kiefer JR; Kleinheinz T; Li Y; Maher J; Pardo E; Poy F; Spillane KL; Wang F; Wang J; Wei X; Xu Z; Xu Z; Yen I; Zawadzke L; Zhu X; Bellon S; Cummings R; Cochran AG; Albrecht BK; Magnuson S
J Med Chem; 2016 Dec; 59(23):10549-10563. PubMed ID: 27682507
[TBL] [Abstract][Full Text] [Related]
3. A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors.
Bronner SM; Murray J; Romero FA; Lai KW; Tsui V; Cyr P; Beresini MH; de Leon Boenig G; Chen Z; Choo EF; Clark KR; Crawford TD; Jayaram H; Kaufman S; Li R; Li Y; Liao J; Liang X; Liu W; Ly J; Maher J; Wai J; Wang F; Zheng A; Zhu X; Magnuson S
J Med Chem; 2017 Dec; 60(24):10151-10171. PubMed ID: 29155580
[TBL] [Abstract][Full Text] [Related]
4. Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors.
Bi X; Chen Y; Sun Z; Lu W; Xu P; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem Lett; 2020 Nov; 30(22):127480. PubMed ID: 32882416
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs.
Katavolos P; Cain G; Farman C; Romero FA; Magnuson S; Ly JQ; Choo EF; Katakam AK; Andaya R; Maher J
Toxicol Pathol; 2020 Apr; 48(3):465-480. PubMed ID: 32124659
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain.
Chen Y; Bi X; Zhang F; Sun Z; Xu P; Jiang H; Lu W; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
Bioorg Chem; 2020 Aug; 101():103991. PubMed ID: 32559581
[TBL] [Abstract][Full Text] [Related]
8. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong
Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
Xiang Q; Wang C; Wu T; Zhang C; Hu Q; Luo G; Hu J; Zhuang X; Zou L; Shen H; Wu X; Zhang Y; Kong X; Liu J; Xu Y
J Med Chem; 2022 Jan; 65(1):785-810. PubMed ID: 34962793
[TBL] [Abstract][Full Text] [Related]
11. Development of Dimethylisoxazole-Attached Imidazo[1,2-
Muthengi A; Wimalasena VK; Yosief HO; Bikowitz MJ; Sigua LH; Wang T; Li D; Gaieb Z; Dhawan G; Liu S; Erickson J; Amaro RE; Schönbrunn E; Qi J; Zhang W
J Med Chem; 2021 May; 64(9):5787-5801. PubMed ID: 33872011
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
[TBL] [Abstract][Full Text] [Related]
13. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.
Lai KW; Romero FA; Tsui V; Beresini MH; de Leon Boenig G; Bronner SM; Chen K; Chen Z; Choo EF; Crawford TD; Cyr P; Kaufman S; Li Y; Liao J; Liu W; Ly J; Murray J; Shen W; Wai J; Wang F; Zhu C; Zhu X; Magnuson S
Bioorg Med Chem Lett; 2018 Jan; 28(1):15-23. PubMed ID: 29169673
[TBL] [Abstract][Full Text] [Related]
16. Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain.
Xu H; Luo G; Wu T; Hu J; Wang C; Wu X; Zhang Y; Xu Y; Xiang Q
Biochem Biophys Res Commun; 2022 Oct; 623():17-22. PubMed ID: 35868068
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors.
Hu H; Wang X; Chan GK; Chang JH; Do S; Drummond J; Ebens A; Lee W; Ly J; Lyssikatos JP; Murray J; Moffat JG; Chao Q; Tsui V; Wallweber H; Kolesnikov A
Bioorg Med Chem Lett; 2015 Nov; 25(22):5258-64. PubMed ID: 26459208
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia.
Xiang Q; Wu T; Zhang C; Wang C; Xu H; Hu Q; Hu J; Luo G; Zhuang X; Wu X; Zhang Y; Xu Y
Bioorg Chem; 2024 Jan; 142():106950. PubMed ID: 37924753
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.
Smith AL; D'Angelo ND; Bo YY; Booker SK; Cee VJ; Herberich B; Hong FT; Jackson CL; Lanman BA; Liu L; Nishimura N; Pettus LH; Reed AB; Tadesse S; Tamayo NA; Wurz RP; Yang K; Andrews KL; Whittington DA; McCarter JD; Miguel TS; Zalameda L; Jiang J; Subramanian R; Mullady EL; Caenepeel S; Freeman DJ; Wang L; Zhang N; Wu T; Hughes PE; Norman MH
J Med Chem; 2012 Jun; 55(11):5188-219. PubMed ID: 22548365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
